{{ $DoctorName }} @if (isset(session()->get('doctor')['vCentralCode'])) {{ session()->get('doctor')['vCentralCode'] }} @endif
@if (isset(session()->get('doctor')['vCentralCode']))
Logout
@endif

{{ $ActivityTypeName }}

{{ $ActivityName }}

@csrf
@if (isset(session()->get('doctor')['vCentralCode']))
Back
@else
@endif
Pexitaz Survey
  1. On an average, how many lung cancer patients visit you in a year? *
  2. In your clinical practice, what percentage of lung cancer patients get diagnosed at following stages *
    3. Stage I
    %
    Stage II
    %
    Stage IIIA
    %
    Stage IIIB
    %
    Stage IV
    %
  3. In your clinical practice, what percentage of lung cancer patients get diagnosed with these histologies *
    4. Small cell lung carcinoma
    %
    Non-small cell lung carcinoma
    %
    Squamous NSCLC
    %
    Non-Squamous NSCLC
    %
  4. What factors do you consider before deciding on the treatment regimen for patients with locally advanced or metastatic non-squamous driver mutation negative NSCLC? *
  5. What is your preferred chemotherapy for patients with locally advanced or metastatic non-squamous driver mutation negative NSCLC? *

  6. In which non- squamous patient subgroup, you will not prefer to use pemetrexed? *

    7. Please mention the alternative molecule that you would prefer in those patients.

    a
    b
    c
    d
  7. What percentage of non-squamous driver mutation negative NSCLC patients take pemetrexed for *
    8. First line
    %
    Second line
    %
    Third line
    %
  8. In your clinical practice, how many cycles of Pemetrexed do you recommend for first line treatment of locally advanced or metastatic non-squamous driver mutation negative NSCLC? *

  9. What percentage of locally advanced or metastatic non-squamous driver mutation negative NSCLC patients achieve following responses after taking Pemetrexed in first line setting. *
    10. Complete Response
    %
    Partial Response
    %
    Stable Disease
    %
    No response
    %
  10. From your clinical experience, Which patient subset is at a risk of early relapse after first line treatment with Pemetrexed? *
  11. In your clinical practice, which molecule do you prefer in second line setting after first line relapsed on pemetrexed for non-squamous driver mutation negative NSCLC patients? *
  12. In your clinical practice, what percentage of lung cancer patients can afford immunotherapy? *
    13. %
  13. Do you recommend pemetrexed in relapsed squamous NSCLC patients who were treated with Gemcitabine in first line setting? *

  14. What percentage of your patients take Pemetrexed for continuous maintenance after completion of induction treatment with Pemetrexed? *
    15. %
  15. Do you recommend switch maintenance with Pemetrexed in non-squamous driver mutation negative NSCLC? *

  16. What percentage of your patients usually take the following doses of Pemetrexed? *
    17. <700mg
    %
    700mg
    %
    750mg
    %
    800mg
    %
    >800mg
    %
  17. What percentage of EGFR mutation positive NSCLC patients take pemetrexed for second line or third line and how many cycles? *
    18. Second line
    %
    Third line
    %
  18. In your clinical practice, will you prefer to use Pemetrexed infusion bags over pemetrexed conventional vials? *